A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia
A Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia
Sponsor: Forest Laboratories
A PHASE3 clinical study on Community-Acquired Bacterial Pneumonia and Lung Infection of Individual Not Recently Hospitalized, this trial is completed. The trial is conducted by Forest Laboratories and has accumulated 8 data snapshots since 2011. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Oct 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Dec 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Forest Laboratories
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Anyang-si, South Korea , Bangalore, India , Beijing, China , Bucheon-si, South Korea , Calicut, India , Can Tho, Vietnam , Chengdu, China , Cheonan-si, South Korea , Chuncheon, South Korea , Daegu, South Korea and 33 more locations